GVK Bio Pens Drug Screening Deal with Temple University's Moulder Center | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Indian contract research organization GVK Biosciences said on Monday that it has entered into a drug screening deal with the Moulder Center for Drug Discovery Research at Temple University.

The multi-year agreement calls for GVK Bio to validate targets and identify and optimize small molecules in specific therapeutic areas, such as cardiovascular, metabolic, and central nervous system disorders.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."